BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief ...
BNT327/ PM8002, an investigational bispecific antibody combining PD-L1 checkpoint inhibition with VEGF-A neutralization being developed in collaboration with Biotheus: For more information, please ...
BioNTech reported Q1 revenue of $192.23 million, surpassing the consensus of $177.40 million. Cash and investments totaled 15.85 billion euros as of March 31, 2025. Geopolitical tensions, Fed ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on discovering and developing antibodies for oncological or inflammatory diseases.
The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay FRANKFURT (Reuters) -Germany's ...
BioNTech's first late-stage cancer trial success Phase III trial shows BNT323 slows HER2-positive breast cancer progression, companies say Companies compete with AstraZeneca-Daiichi alliance For COVID ...
We recently published 11 Best Cancer Stocks to Buy Right Now. BioNTech SE is one of them. BioNTech SE (NASDAQ:BNTX), a German biotechnology company, specializes in mRNA-based immunotherapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results